ParkinsonCanadaV1, France, Analysis, bibRecord, 000271

Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque

Identifieur interne : 000271 ( France/Analysis ); précédent : 000270; suivant : 000272

Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque

Auteurs : Erwan Bezard [France] ; Michael P. Hill [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Anne Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique]

Source :

European journal of pharmacology [ 0014-2999 ] ; 2004.

RBID : Pascal:04-0478153

Descripteurs français

Pascal (Inist)
- Lévétiracétam, Lévodopa, Dyskinésie, Neurotoxine, Psychotrope, Nootrope, Antiparkinsonien, MPTP.

English descriptors

KwdEn :
- Antiparkinson agent, Dyskinesia, Levetiracetam, Levodopa, Neurotoxin, Nootropic agent, Psychotropic.

Abstract

L-3,4 dihydroxyphenylalanine (levodopa)-induced dyskinesia in Parkinson's disease patients is characterized by a mixture of chorea and dystonia. Electrophysiological studies suggest that chorea is associated with abnormal synchronization of firing of basal ganglia neurons while dystonia is not. Levetiracetam is a novel anti-epileptic drug known to exhibit unique desynchronizing properties in contrast to other anti-epileptic drugs. We assessed the anti-dyskinetic efficacy of levetiracetam (13, 30 and 60 mg/kg, p.o.) administered in combination with an individually tailored dose of levodopa (Levodopa/carbidopa, 4:1 ratio, 19 ± 1.8 mg/kg, p.o.), in six dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned macaques. Levetiracetam (60 mg/kg) significantly reduced levodopa-induced chorea during the first hour post-treatment but had no effect on dystonia. Levetiracetam, at all doses tested, had no effect on the anti-parkinsonian action of levodopa. These results suggest that levetiracetam may provide a novel therapeutic approach specifically aimed at the choreic form of levodopa-induced dyskinesia.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000967
to stream PascalFrancis, to step Curation: 000356
to stream PascalFrancis, to step Checkpoint: 000871
to stream Main, to step Merge: 003093
to stream Main, to step Curation: 002D24
to stream Main, to step Exploration: 002D24
to stream France, to step Extraction: 000271

Links to Exploration step

Pascal:04-0478153

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque</title>
<author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite Victor Segalen-Bordeaux 2, 146 rue Leo Saignat, BP 28</s1>
<s2>33076 Bordeaux</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>33076 Bordeaux</wicri:noRegion>
<wicri:noRegion>BP 28</wicri:noRegion>
<wicri:noRegion>33076 Bordeaux</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Motac Neuroscience Ltd., Williams House, Manchester Science Park, Lloyd Street North</s1>
<s2>Manchester M15 6SE</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Manchester M15 6SE</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Motac Neuroscience Ltd., Williams House, Manchester Science Park, Lloyd Street North</s1>
<s2>Manchester M15 6SE</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Manchester M15 6SE</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>School of Biological Sciences, University of Manchester, 1. 124 Stop ford Building, Oxford Road</s1>
<s2>Manchester M13 9PT</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Manchester M13 9PT</wicri:noRegion>
<orgName type="university">Université de Manchester</orgName>
<placeName><settlement type="city">Manchester</settlement>
<region type="nation">Angleterre</region>
<region nuts="2" type="region">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Applied and Interventional Research, Toronto Western Research Institute, McLaughlin Wing, Room 11-419, 399 Bathurst Street</s1>
<s2>Toronto, ON, M5T 2S8</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, ON, M5T 2S8</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Michel, Anne" sort="Michel, Anne" uniqKey="Michel A" first="Anne" last="Michel">Anne Michel</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>UCB S.A., Pharma Sector, Preclinical CNS Research, Chemin du Foriest</s1>
<s2>1420 Braine L'Alleud</s2>
<s3>BEL</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><region type="land" nuts="2">Vienne (Autriche)</region>
<settlement type="city">Vienne (Autriche)</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Grimee, Renee" sort="Grimee, Renee" uniqKey="Grimee R" first="Renee" last="Grimee">Renee Grimee</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>UCB S.A., Pharma Sector, Preclinical CNS Research, Chemin du Foriest</s1>
<s2>1420 Braine L'Alleud</s2>
<s3>BEL</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><region type="land" nuts="2">Vienne (Autriche)</region>
<settlement type="city">Vienne (Autriche)</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Klitgaard, Henrik" sort="Klitgaard, Henrik" uniqKey="Klitgaard H" first="Henrik" last="Klitgaard">Henrik Klitgaard</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>UCB S.A., Pharma Sector, Preclinical CNS Research, Chemin du Foriest</s1>
<s2>1420 Braine L'Alleud</s2>
<s3>BEL</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><region type="land" nuts="2">Vienne (Autriche)</region>
<settlement type="city">Vienne (Autriche)</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0478153</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0478153 INIST</idno>
<idno type="RBID">Pascal:04-0478153</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000967</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000356</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000871</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000871</idno>
<idno type="wicri:doubleKey">0014-2999:2004:Bezard E:levetiracetam:improves:choreic</idno>
<idno type="wicri:Area/Main/Merge">003093</idno>
<idno type="wicri:Area/Main/Curation">002D24</idno>
<idno type="wicri:Area/Main/Exploration">002D24</idno>
<idno type="wicri:Area/France/Extraction">000271</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque</title>
<author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Universite Victor Segalen-Bordeaux 2, 146 rue Leo Saignat, BP 28</s1>
<s2>33076 Bordeaux</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region>
<region type="old region" nuts="2">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Motac Neuroscience Ltd., Williams House, Manchester Science Park, Lloyd Street North</s1>
<s2>Manchester M15 6SE</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Manchester M15 6SE</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Motac Neuroscience Ltd., Williams House, Manchester Science Park, Lloyd Street North</s1>
<s2>Manchester M15 6SE</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Manchester M15 6SE</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="03"><s1>School of Biological Sciences, University of Manchester, 1. 124 Stop ford Building, Oxford Road</s1>
<s2>Manchester M13 9PT</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>Manchester M13 9PT</wicri:noRegion>
<orgName type="university">Université de Manchester</orgName>
<placeName><settlement type="city">Manchester</settlement>
<region type="nation">Angleterre</region>
<region nuts="2" type="region">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Division of Applied and Interventional Research, Toronto Western Research Institute, McLaughlin Wing, Room 11-419, 399 Bathurst Street</s1>
<s2>Toronto, ON, M5T 2S8</s2>
<s3>CAN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Toronto, ON, M5T 2S8</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Michel, Anne" sort="Michel, Anne" uniqKey="Michel A" first="Anne" last="Michel">Anne Michel</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>UCB S.A., Pharma Sector, Preclinical CNS Research, Chemin du Foriest</s1>
<s2>1420 Braine L'Alleud</s2>
<s3>BEL</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><region type="land" nuts="2">Vienne (Autriche)</region>
<settlement type="city">Vienne (Autriche)</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Grimee, Renee" sort="Grimee, Renee" uniqKey="Grimee R" first="Renee" last="Grimee">Renee Grimee</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>UCB S.A., Pharma Sector, Preclinical CNS Research, Chemin du Foriest</s1>
<s2>1420 Braine L'Alleud</s2>
<s3>BEL</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><region type="land" nuts="2">Vienne (Autriche)</region>
<settlement type="city">Vienne (Autriche)</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Klitgaard, Henrik" sort="Klitgaard, Henrik" uniqKey="Klitgaard H" first="Henrik" last="Klitgaard">Henrik Klitgaard</name>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>UCB S.A., Pharma Sector, Preclinical CNS Research, Chemin du Foriest</s1>
<s2>1420 Braine L'Alleud</s2>
<s3>BEL</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><region type="land" nuts="2">Vienne (Autriche)</region>
<settlement type="city">Vienne (Autriche)</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">European journal of pharmacology</title>
<title level="j" type="abbreviated">Eur. j. pharmacol.</title>
<idno type="ISSN">0014-2999</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">European journal of pharmacology</title>
<title level="j" type="abbreviated">Eur. j. pharmacol.</title>
<idno type="ISSN">0014-2999</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Dyskinesia</term>
<term>Levetiracetam</term>
<term>Levodopa</term>
<term>Neurotoxin</term>
<term>Nootropic agent</term>
<term>Psychotropic</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lévétiracétam</term>
<term>Lévodopa</term>
<term>Dyskinésie</term>
<term>Neurotoxine</term>
<term>Psychotrope</term>
<term>Nootrope</term>
<term>Antiparkinsonien</term>
<term>MPTP</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">L-3,4 dihydroxyphenylalanine (levodopa)-induced dyskinesia in Parkinson's disease patients is characterized by a mixture of chorea and dystonia. Electrophysiological studies suggest that chorea is associated with abnormal synchronization of firing of basal ganglia neurons while dystonia is not. Levetiracetam is a novel anti-epileptic drug known to exhibit unique desynchronizing properties in contrast to other anti-epileptic drugs. We assessed the anti-dyskinetic efficacy of levetiracetam (13, 30 and 60 mg/kg, p.o.) administered in combination with an individually tailored dose of levodopa (Levodopa/carbidopa, 4:1 ratio, 19 ± 1.8 mg/kg, p.o.), in six dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned macaques. Levetiracetam (60 mg/kg) significantly reduced levodopa-induced chorea during the first hour post-treatment but had no effect on dystonia. Levetiracetam, at all doses tested, had no effect on the anti-parkinsonian action of levodopa. These results suggest that levetiracetam may provide a novel therapeutic approach specifically aimed at the choreic form of levodopa-induced dyskinesia.</div>
</front>
</TEI>
<affiliations><list><country><li>Belgique</li>
<li>Canada</li>
<li>France</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Aquitaine</li>
<li>Grand Manchester</li>
<li>Nouvelle-Aquitaine</li>
<li>Vienne (Autriche)</li>
</region>
<settlement><li>Bordeaux</li>
<li>Manchester</li>
<li>Vienne (Autriche)</li>
</settlement>
<orgName><li>Université de Manchester</li>
</orgName>
</list>
<tree><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name>
</region>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name>
</noRegion>
<name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name>
<name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name>
</country>
<country name="Canada"><noRegion><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
</noRegion>
</country>
<country name="Belgique"><region name="Vienne (Autriche)"><name sortKey="Michel, Anne" sort="Michel, Anne" uniqKey="Michel A" first="Anne" last="Michel">Anne Michel</name>
</region>
<name sortKey="Grimee, Renee" sort="Grimee, Renee" uniqKey="Grimee R" first="Renee" last="Grimee">Renee Grimee</name>
<name sortKey="Klitgaard, Henrik" sort="Klitgaard, Henrik" uniqKey="Klitgaard H" first="Henrik" last="Klitgaard">Henrik Klitgaard</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000271 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000271 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     Pascal:04-0478153
   |texte=   Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque

Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri